
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Human Cancer Biology |
Authors' Affiliations: 1 Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche/Dipartimento di Biologia e Patologia Cellulare e Molecolare, 2 Dipartimento Assistenziale di Otorinolaringoiatria e Scienze Affini, and 3 Dipartimento di Scienze Biomorfologiche e Funzionali, University of Naples "Federico II," Naples, Italy
Requests for reprints: Massimo Santoro, Dipartimento di Biologia e Patologia Cellulare e Molecolare, University of Naples "Federico II," via S. Pansini 5, 80131 Naples, Italy. Phone: 39-81-7463056; Fax: 39-81-7463037; E-mail: masantor{at}unina.it.
Purpose: Osteopontin is a secreted cytokine that binds to the cell surface CD44v6 receptor. We studied osteopontin and CD44v6 expression in laryngeal squamous cell carcinomas and correlated osteopontin expression levels with clinicopathologic tumor features.
Experimental Design: We used immunohistochemistry, immunoblotting, and reverse transcription-PCR to study osteopontin expression in 58 laryngeal squamous cell carcinomas. Cultured squamous carcinoma cells were treated with exogenous osteopontin or with RNA interference to knockdown osteopontin expression.
Results: Osteopontin expression was higher in all the invasive carcinomas than in patient-matched normal mucosa. Its expression levels were significantly correlated with tumor stage and grade and with the presence of lymph node and distant metastases. Osteopontin positivity was negatively correlated with overall survival (P = 0.03). Osteopontin expression was paralleled by intense cell surface reactivity for CD44v6. Treatment of squamous carcinoma cells with recombinant osteopontin sharply increased proliferation and Matrigel invasion in comparison with the untreated cells parallel to activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase signaling cascade. Osteopontin knockdown by RNA interference, anti-CD44 antibodies, and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibition prevented these effects.
Conclusions: These results identify osteopontin as a marker and a potential therapeutic target in cases of aggressive laryngeal squamous cell carcinomas.
This article has been cited by other articles:
![]() |
M. Suzuki, E. Mose, C. Galloy, and D. Tarin Osteopontin Gene Expression Determines Spontaneous Metastatic Performance of Orthotopic Human Breast Cancer Xenografts Am. J. Pathol., August 1, 2007; 171(2): 682 - 692. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bloomston, E. C. Ellison, P. Muscarella, O. Al-Saif, E. W. Martin, W. S. Melvin, and W. L. Frankel Stromal Osteonectin Overexpression Is Associated with Poor Outcome in Patients with Ampullary Cancer Ann. Surg. Oncol., January 1, 2007; 14(1): 211 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J White, R. C Burghardt, J. Hu, M. M Joyce, T. E Spencer, and G. A Johnson Secreted phosphoprotein 1 (osteopontin) is expressed by stromal macrophages in cyclic and pregnant endometrium of mice, but is induced by estrogen in luminal epithelium during conceptus attachment for implantation. Reproduction, December 1, 2006; 132(6): 919 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Petrik, P. W. Lavori, H. Cao, Y. Zhu, P. Wong, E. Christofferson, M. J. Kaplan, H. A. Pinto, P. Sutphin, A. C. Koong, et al. Plasma Osteopontin Is an Independent Prognostic Marker for Head and Neck Cancers J. Clin. Oncol., November 20, 2006; 24(33): 5291 - 5297. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |